Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study
about
Temsirolimus inhibits proliferation and migration in retinal pigment epithelial and endothelial cells via mTOR inhibition and decreases VEGF and PDGF expressionInterobserver agreement in clinical grading of vitreous haze using alternative grading scales.Pharmacotherapy for uveitis: current management and emerging therapy.Review of Systemic Immunosuppression for Autoimmune UveitisLocal therapies for inflammatory eye disease in translation: past, present and futureIntravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trialRapamycin inhibits the production of myofibroblasts and reduces corneal scarring after photorefractive keratectomy.Subconjunctival sirolimus in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I/II clinical trialSurface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin.Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patientsClinical trials in noninfectious uveitisThe Neuroprotective Effect of Rapamycin as a Modulator of the mTOR-NF-κB Axis during Retinal InflammationUnderstanding autoimmunity in the eye: from animal models to novel therapies.Assessment of vitreous haze using ultra-wide field retinal imaging.The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates.In Vitro and In Vivo Sustained Zero-Order Delivery of Rapamycin (Sirolimus) From a Biodegradable Intraocular Device.Birdshot uveitis: current and emerging treatment optionsNovel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye.Emerging therapies for noninfectious uveitis: what may be coming to the clinicsA comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I.New pharmacotherapy options for noninfectious posterior uveitis.Moving forward in uveitis therapy: preclinical to phase II clinical trial drug development.Non-Infectious Uveitis: Optimising the Therapeutic Response.Uveitic macular edema.Sirolimus for the treatment of noninfectious uveitis.The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society Thesis).Nanomicellar Topical Aqueous Drop Formulation of Rapamycin for Back-of-the-Eye Delivery.One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis.The Effect of Transient Local Anti-inflammatory Treatment on the Survival of Pig Retinal Progenitor Cell Allotransplants.Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Behçet disease.The Suppression of Wound Healing Response with Sirolimus and Sunitinib Following Experimental Trabeculectomy in a Rabbit Model.Intravitreal therapeutic agents in noninfectious uveitic macular edema
P2860
Q28540142-072ABF84-C4AE-49DE-8B8D-C49CFCCC93D8Q34005672-3BD1435E-442B-4FB9-9A90-AD0C8AC20AD7Q34274075-746CCC89-94FC-4503-A4AF-BE21CA29EF46Q34627012-477157D6-1CEE-459B-9E31-78279B1D7519Q34892662-1209BC45-0A87-457E-99DE-6C6D7BFC9843Q34956193-EC83D731-0F83-4437-9659-80AD5537D703Q35012339-C9C518ED-91DF-4F52-91C6-E7AA3B79314DQ35085846-9AF15385-2E04-42A7-888E-CE11F9575CA3Q35087664-E0C6781B-3B4E-4072-BB75-6370A8287DB2Q35478602-B5969985-FCBC-43AE-9B76-EE609C020081Q35681664-6546426F-4150-45AD-B14A-90C19EA932D7Q35895350-AD687425-7DE1-41C6-B3E8-777847260886Q36069594-8B205E6F-C3EB-42AD-AF2E-6451DDEC11BDQ36149355-B0DADB9E-2E13-4F92-8B69-112009ECAEAEQ36217662-190CE804-6B48-4787-A2B5-A7B959797670Q36273801-2D811A3A-5331-4053-8BD4-A78E066B8D50Q37412317-5DAAA445-1F2F-4614-A3EA-5F6731CB5015Q38211433-E74D3AF1-02D9-4A16-AA21-FCD34DB26263Q38215514-48E1EA31-7E9F-4EFE-B734-EC0E4F3E9781Q38250116-82F370EA-3C10-47D9-81EA-D9355FFC40B7Q38253095-3D043A35-42DE-4DE0-8504-EB3C721C5518Q38660708-A793E529-AB64-4E27-A01F-009755661F6AQ38662045-299E6955-880D-44AF-8420-097D6F0139F8Q38852119-CB201F69-ED0B-416D-9B55-371121C5E6ACQ38938749-8EF1EB38-068B-4F81-A2B1-271181CD06A8Q40539739-FB0794FE-489A-4B7A-9B7A-9F5B021040E1Q41109836-C83B0790-E6FC-44BD-81B6-6DECE7D8B40CQ41429564-443C0C45-9272-4A3C-8842-FE906E720C26Q42117963-88238352-EF30-4EDE-9327-4E36412402FDQ53314850-9063D59E-68E4-4A75-853E-DB17D87292C2Q53535205-C34C9999-BE04-4024-92EC-425E6681F02CQ58806282-10816CEF-5C46-462A-8EB2-F2BAFE44E71F
P2860
Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Ocular tolerability and effica ...... onth results of the SAVE Study
@ast
Ocular tolerability and effica ...... onth results of the SAVE Study
@en
type
label
Ocular tolerability and effica ...... onth results of the SAVE Study
@ast
Ocular tolerability and effica ...... onth results of the SAVE Study
@en
prefLabel
Ocular tolerability and effica ...... onth results of the SAVE Study
@ast
Ocular tolerability and effica ...... onth results of the SAVE Study
@en
P2093
P2860
P356
P1476
Ocular tolerability and effica ...... onth results of the SAVE Study
@en
P2093
Anthony Watters
Diana V Do
Henry Alexander Leder
James P Dunn
Jithin Yohannan
Millena Bittencourt
Mohamed A Ibrahim
Naveed Shams
Ovais Shaikh
P2860
P2888
P356
10.1186/1869-5760-3-32
P577
2013-02-11T00:00:00Z
P5875
P6179
1027319772